Anti-inflammatory effects of a novel compound, MPQP, through the inhibition of IRAK1 signaling pathways in LPS-stimulated RAW 264.7 macrophages
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ba Reum | - |
dc.contributor.author | Cho, Young-Chang | - |
dc.contributor.author | Cho, Sayeon | - |
dc.date.available | 2019-01-22T14:20:21Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.issn | 1976-670X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/1514 | - |
dc.description.abstract | Small-molecule inhibitors are widely used to treat a variety of inflammatory diseases. In this study, we found a novel anti-inflammatory compound, 1-[(2R,45)-2-methyl-4-(phenylamino)-1,2,3,4-tetrahydroquinolin-1-yl]prop-2-en-1-one (MPQP). It showed strong anti-inflammatory effects in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. These effects were exerted through the inhibition of the production of NO and pro-inflammatory cytokines, such as interleukin (IL)-6, IL-1 beta, and tumor necrosis factor-alpha (TNF-alpha). Furthermore, MPQP decreased the expression levels of inducible NO synthase (iNOS) and cyclooxygenase 2 (COX-2). Additionally, it mediated the inhibition of the phosphorylation of p38, c-Jun N-terrninal kinase (JNK), the inhibitor of kappa B alpha (I kappa B alpha), and their upstream kinases, I kappa B kinase (IKK) alpha/beta, mitogen-activated protein kinase kinase (MKK) 3/6, and MKK4. Furthermore, the expression of IL-1 receptor-associated kinase 1 (IRAK1) that regulates NF-kappa B, p38, and the JNK signaling pathways, was also increased by MPQP. These results indicate that MPQP regulates the IRAK1-mediated inflammatory signaling pathways by targeting IRAK1 or its upstream factors. | - |
dc.format.extent | 6 | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.title | Anti-inflammatory effects of a novel compound, MPQP, through the inhibition of IRAK1 signaling pathways in LPS-stimulated RAW 264.7 macrophages | - |
dc.type | Article | - |
dc.identifier.doi | 10.5483/BMBRep.2018.51.6.064 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.51, no.6, pp 308 - 313 | - |
dc.identifier.kciid | ART002356602 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000439689200009 | - |
dc.identifier.scopusid | 2-s2.0-85049449383 | - |
dc.citation.endPage | 313 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 308 | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 51 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Cyclooxygenase 2 | - |
dc.subject.keywordAuthor | IL-1 receptor-associated kinase 1 | - |
dc.subject.keywordAuthor | Inflammation | - |
dc.subject.keywordAuthor | Inflammatory cytokine | - |
dc.subject.keywordAuthor | 1-[(2R,4S)-2-methyl-4-(phenylamino)-1,2,3,4-tetrahydroquinolin-l-yl]prop -2-en-1-one | - |
dc.subject.keywordPlus | INDUCED INFLAMMATORY MEDIATORS | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | KAPPA-B | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | AGENTS | - |
dc.subject.keywordPlus | DERIVATIVES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | QUINOLINE | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.